✦ LIBER ✦

Pharmacokinetics, pharmacodynamics, and tolerability of the dipeptidyl peptidase IV inhibitor LC15-0444 in healthy Korean men: A dose—block-randomized, double-blind, placebo-controlled, ascending single-dose, phase I study

✍ Scribed by Kyoung Soo Lim; Jung-Ryul Kim; Yun-Jung Choi; Kwang-Hee Shin; Kyu-Pyo Kim; Jang-Hee Hong; Joo-Youn Cho; Hyun-Suk Shin; Kyung-Sang Yu; Sang-Goo Shin; O Hwan Kwon; Dal-Mi Hwang; Jeong-Ae Kim; In-Jin Jang

Book ID: 116372229
Publisher: Elsevier Science
Year: 2008
Tongue: English
Weight: 169 KB
Volume: 30
Category: Article
ISSN: 0149-2918
DOI: 10.1016/j.clinthera.2008.10.013

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Pharmacokinetic and Pharmacodynamic Asse

Pharmacokinetic and Pharmacodynamic Assessments of the Dipeptidyl Peptidase-4 Inhibitor PHX1149: Double-Blind, Placebo-Controlled, Single- and Multiple-Dose Studies in Healthy Subjects

✍ A. Marie O'Farrell; Andre van Vliet; Khalid Abou Farha; Julie M. Cherrington; Da 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 898 KB

Tolerability and pharmacokinetics of ava

Tolerability and pharmacokinetics of avanafil, a phosphodiesterase type 5 inhibitor: A single- and multiple-dose, double-blind, randomized, placebo-controlled, dose-escalation study in healthy Korean male volunteers

✍ Jinah Jung; Sangmin Choi; Sang Heon Cho; Jong-Lyul Ghim; Aekyung Hwang; Unjib Ki 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 128 KB

Pharmacokinetic, pharmacodynamic, and to

Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor alogliptin: A randomized, double-blind, placebo-controlled, multiple-dose study in adult patients with type 2 diabetes

✍ Paul Covington; Ronald Christopher; Michael Davenport; Penny Fleck; Qais A. Mekk 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 253 KB

737 A PHASE-I, RANDOMIZED, DOUBLE-BLIND,

737 A PHASE-I, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF SINGLE ESCALATING ORAL DOSES OF GS-9620 IN HEALTHY SUBJECTS

✍ U. Lopatin; G. Wolfgang; R. Kimberlin; D. Turnas; M. Cornprost; G. Chittick; C. 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 46 KB

561 Safety and pharmacokinetics of the n

561 Safety and pharmacokinetics of the now nucleoside polymerase inhibitor, HCV-796: Results of a randomized, double-blind, placebo-controlled, ascending single-dose study in healthy subjects

✍ P. Chandra; D. Raible; L. Moyer; D. Harper; J. Speth; S. Villano; R. Fruncillo 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 235 KB

Effects of the Src kinase inhibitor sara

Effects of the Src kinase inhibitor saracatinib (AZD0530) on bone turnover in healthy men: A randomized, double-blind, placebo-controlled, multiple-ascending-dose phase I trial

✍ Rosemary A Hannon; Glen Clack; Martin Rimmer; Alan Swaisland; J Andrew Lockton; 📂 Article 📅 2010 🏛 American Society for Bone and Mineral Research 🌐 English ⚖ 243 KB